Member Info for Shakeyerbooty

Come on O&W.Algw is Main Market!

later ITV 7.30 pm.Are UK authorities equipped to deal with the Coronavirus? I can tell them the answer now.

We're already producing you idiot.Do some research!

Methods

MATINS (Macrophage Antibody To INhibit immune Suppression) trial is a multicenter first-in-human phase I/II study (NCT03733990) to assess the tolerability, safety and preliminary efficacy of FP-1305 in patients with advanced, IO-refractory melanoma, cholangiocarcinoma, hepatocellular, colorectal, and pancreatic ductal adenocarcinoma. Biomarker analysis included CLEVER-1 determination, immune cell profiling by mass cytometry and analysis of cytokine production.

Results

11 patients (median age 57) were enrolled in four cohorts (0.3, 1.0, 3.0 or 10?mg/kg) and received 1-8 cycles (median 3) of FP-1305 every three weeks. FP-1305 has been well tolerated without dose-limiting toxicities and maximum tolerated dose (MTD) has not been reached. Promising early efficacy results have recently been reported (ESMO 2019, LBA19). FP-1305 dosing led to increased Th1 skewing (CXCR3+CCR6-) of CD4 and CD8 T cell populations with downregulation of several inhibitory immune checkpoint molecules. Increase in circulating IFN gamma was detected but it was most prominent in the patient showing durable partial response.

Conclusion

FP-1305 is the first macrophage checkpoint inhibitor candidate promoting immune switch with promising tolerability and clinical anti-tumor activity. FP-1305 represents a novel treatment option to provoke immune response against cold tumors.

Clinical trial identification

NCT03733990.

Legal entity responsible for the study

Faron Pharmaceuticals.

this17 Dec '19 - 08:37 - 1394 of 1394
0 0 0
Faron will be at Esmo’s Immuno-Oncology Congress on 13.12, Geneve:

Mini Oral session 2

Date
13.12.2019

Lecture Time
08:00 - 08:00
Mini Oral session
2O - Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours

Presentation Number
2O
Lecture Time
08:00 - 08:05
Speakers
M. Hollmén (Turku, Finland)
Authors
M. Hollmén (Turku, Finland) R. Virtakoivu (Turku, Finland) P. Jaakkola (Helsinki, Finland) A. Minchom (London, United Kingdom) S. Jalkanen (Turku, Finland) M. Karvonen (Turku, Finland) J. Mandelin (Turku, Finland) J. Koivunen (Oulu, Switzerland) P. Bono (Helsinki, Finland)
Abstract
Background

A scavenger receptor CLEVER-1 is highly expressed on tumor associated macrophages (TAMs) and mediates the clearance of “unwanted” self-components. Pre-clinical studies demonstrate that CLEVER-1 inhibition increases TAM pro-inflammatory cytokine secretion and antigen presentation reactivating CD8+ T cell responses with robust anti-tumor activity (Viitala et al., 2019). Targeting CLEVER-1 could overcome the immunosuppressive tumor microenvironment and has led to the development of FP-1305, a humanized anti-CLEVER-1 IgG4-antibody.

Clearly you don't get out of your own house then Paulie0101.I know plenty who are switching from Labour to Tory.Labour will bankrupt this country again.The thought of Corbin,Abacus and McDonut running this country sends shivers through their spine.

It's market cap that matters,not share price.Jeez.Some people really should not be anywhere near the stockmarket.

Give it a rest Casper786.We don't need you ramping this every 5 seconds.We know exactly what we've got here and its worth.You were exactly the same on NUOG with your use of block capitals and look where that is now.Chill out.

No it isn't.You've gained 18 quid out of 20 quid (i.e a 90% return).

So you said yesterday.You don't need to repeat it.Just to emphasise,a shorter can only make a maximum of 100% on an individual trade whereas the return on a long is unlimited.I prefer to be long.

Croz-If you'd have done that with SLN,you'd have lost out big time.WE ARE IN TALKS WITH MULTIPLE POTENTIAL LICENCEES in Japan & Asia.It's possible we will get more than one deal signed.

I wonder if Fund Managers running Income based funds are looking at EUA now m/c is increasing.

It does seem to be playing out Re Nicola Duke's chart i.e a drop into the 10's before moving up to her next target 21.96p.

Generally the way to make money is to buy before the news comes out officially.This is Main market listed with a small free float.It will be very difficult to buy large quantities after news.

shandypants-It's not a rumour though is it? The Times clearly got a heads-up from someone and were correct in saying it was a Japanese Company (even specifically mentioning who it was).NFX then confirmed they were in discussions with multiple potential licencees in Japan & Asia.So,the Times were correct.Now one has to question where did the figures come from? Clearly someone at the Times has seen or heard specific information.NFX obviously can't announce those figures until discussions have completed & contracts signed,but there is obviously more to this than meets the eye.The fibrosis market is huge for NXP002.We know cocrystal tech works.This small company from Cambridge is going to be huge.

This hasn't even got to the highs we reached after the Ebers news and NXP001 results.The figures in the Times article relate only to the discussions with the Japanese pharma co.We now know we are in MULTIPLE discussions with other Asian co's.Even if we got a 10% margin on £200m annual royalties over 10 yrs as JW said then this is £200m alone (40p per share) plus the upfront £15m.Now,add on multiple deals with other co's and you can see where this is heading.Main Market and small free float as well.Can't wait for the next bit of news.

Slinky-0.5p-1.5p is actually a 200% rise.Are you Dodge100 in disguise? He couldn't do percentages either.

I suppose the equivalent rise in price compared to BMN would be a rise from 0.11p to 2.5p ish.Very Very likely in the next six months.

It makes me laugh.What do people think 'later this week' means? It doesn't mean early this week! It means later.My expectation is Thurs or Fri.BP could be in production by Xmas (not long to wait) and we'll be financed & prepping for the most profligate diamond field in the world..

A bit like this post of yours from 12th Oct eh MagicMan01.
12 Oct 2019 20:51
Got to get to 0.5 next week surely. There’s so much news coming. I think that’s a reasonable expectation?